Drug intelligence / Profile preview

BAY 987443

Development stage
Phase 2
Lead developer
Bayer
Modality
Small Molecules
Administration
Implant
01

Overview

BAY 987443 is an investigational drug-device combination intrauterine system (IUS) developed by Bayer AG for long-acting reversible contraception. It consists of a levonorgestrel-releasing reservoir (releasing approximately 8 μg/24h) and an additional reservoir containing indomethacin, a nonsteroidal anti-inflammatory drug (NSAID). The system is designed to provide effective contraception while utilizing the cyclooxygenase (COX) inhibiting properties of indomethacin to reduce the uterine bleeding and spotting often experienced by women during the initial months following IUS placement. It has been evaluated in Phase 2 clinical trials (NCT03562624) comparing different indomethacin release rates against a levonorgestrel-only IUS (Jaydess) to optimize the dose-response relationship for bleeding control.

Other names
levonorgestrel/indomethacin IUS
02

Targets

PGHS-1 (Prostaglandin G/H Synthase 1)PTGS2 (Prostaglandin-Endoperoxide Synthase 2)PR (Progesterone receptor)

Beyond the preview

Go deeper on BAY 987443.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on BAY 987443.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call